



- (51) **International Patent Classification:**
C12N 15/74 (2006.01) *C12R 1/01* (2006.01)
- (21) **International Application Number:**
PCT/EP2014/076189
- (22) **International Filing Date:**
2 December 2014 (02.12.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
13195578.3 3 December 2013 (03.12.2013) EP
- (71) **Applicant (for all designated States except US):** **SYM-RISE AG** [DE/DE]; Mühlenfeldstraße 1, 37603 Holz-
minden (DE).
- (72) **Inventors; and**
- (71) **Applicants (for US only):** **FLEIGE, Christian** [DE/DE];
Graf-von-Hövel Straße 9, 59075 Hamm (DE). **LAM-
BRECHT, Stefan** [DE/DE]; Am Kuhkamp 1, 37619
Hehlen (DE). **PESARO, Manuel** [DE/DE]; Schlosshof 3c,
- (74) **Agent:** **FABRY, Bernd**; IP2 Patentanwalts GmbH,
Schlossstraße 523-525, 41238 Mönchengladbach (DE).
- (81) **Designated States (unless otherwise indicated, for every
kind of national protection available):** AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States (unless otherwise indicated, for every
kind of regional protection available):** ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

[Continued on next page]


(54) **Title:** SHUTTLE VECTORS AND EXPRESSION VECTORS FOR AMYCOLATOPSIS

Figure 1
Physical map of the new shuttle vector p6apra

(57) **Abstract:** Suggested is a new shuttle vector (p6apra) with resistance to apramycin obtainable in that shuttle vector pRL6 of *E.coli*-Amycolatopsis (a) is subjected to digestion with a suitable endonuclease (SmaI, XmaI) to remove the npt gene from said vector or the vector backbone is amplified by inverse PCR without the npt gene and (b) the apramycin resistance gene *aac(3)VI* is inserted into the vector backbone by ligation. And also 4 new expression vectors obtained therefrom.



LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, **Published:**

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

5 SHUTTLE VECTORS AND EXPRESSION VECTORS FOR AMYCOLATOPSIS

FIELD OF INVENTION

- 10 The present invention belongs to the area of genetic engineering and covers new shuttle and expression vectors for *Amycolatopsis* sp. ATCC 39116, processes for obtaining them and their application, particular in the production of nature-identic vanillin.

STATE OF THE ART

- 15 The tremendous progress in the development of DNA sequencing and manipulation techniques, which were established in the past decades, stimulated the targeted design of microbial production strains for various applications. One prominent example is the production of amino acids, such as L-lysine or L-glutamate by *Corynebacterium glutamicum* [2].
- 20 Economic interests as well as the increasing demand for sustainable, bio-based products, require the improvement of fermentative production processes, which often have to compete with cheaper chemical approaches. Apart from the optimization of the fermentative process by chemical engineering, the application of metabolic engineering for the generation of improved production strains provides the largest potential to develop
- 25 profitable processes [20].

- The actinomycete *Amycolatopsis* sp. ATCC 39116 is used by the industry for the fermentative production of vanillin from ferulic acid, which is a cell wall component of higher plants [15]. In this case the produced vanillin can be labelled as 'natural' since it is extracted from natural sources or "obtained by appropriate physical, enzymatic or microbiological processes
- 30 from material of vegetable, animal or microbiological origin" (European Commission (EC) Regulation No 1334/2008) [9]. Since natural vanillin has a remarkably higher market price in comparison to the chemically synthesized 'nature-identical' version (up to 1000-fold), this approach can compete with the cheaper chemical processes based on petrochemicals or lignin derivatives [6].

- 35 In order to stop the catabolism of the produced vanillin and therefore to achieve higher vanillin yields and concentrations in production, first attempts were made to engineer the metabolism of *Amycolatopsis* sp. ATCC 39116 and related bacteria [8, 10, 18, 21]. To gain further access to an efficient genetic engineering of *Amycolatopsis* sp. ATCC 39116, new molecular tools have to be developed.

Overexpression of native or heterologous genes in microorganisms can lead to a significant improvement of biotechnological production strains. Beside the systematic deletion or down-regulation of genes, which are involved in catabolic or competing pathways of the desired product, the controlled expression of anabolism related genes is also important to introduce rational changes in the genetic background of the used organism [20].

The capability to overexpress native or foreign genes depends on the availability of host-vector systems such as plasmids, genetic elements like functional promoters and efficient transformation protocols. Although some techniques can be adopted from phylogenetically related bacteria, each part has to be developed individually for a particular bacterial strain [23].

Actinomycetes produce a remarkable amount of secondary metabolites that are industrially used in fields like agriculture, food production and especially pharmacology [17]. Thus, they have been intensively studied aiming at higher titers of the compound of interest or at producing new metabolites with different bioactive functions. Within the group of actinobacteria research on engineering of *Streptomyces* genomes is noteworthy. Besides the commonly used *E. coli* systems, heterologous expression in *Streptomyces* is well established and often used for genes, which are of actinobacterial origin. However, most systems are of limited utility for other Actinomycetes such as *Nocardia* or *Amycolatopsis*.

To make *Amycolatopsis* sp. HR167, whose 16S-rDNA-sequence is identical to that of *Amycolatopsis* sp. ATCC 39116, accessible for genetic engineering. The generation of pRLE6, an *E. coli*-*Amycolatopsis* shuttle vector based on the origin of replication of the indigenous plasmid pA387 from *Amycolatopsis benzoatilytica* DSM 43387 is known from the state of the art [14]. Plasmid pRLE6 is a religated EcoRI-fragment of the *Amycolatopsis mediterranei* shuttle vector pRL60 lacking the erythromycin resistance- and the α -amylase gene. The vector also replicates autonomously in *Amycolatopsis* sp. ATCC 39116 without further deletions or rearrangement. However, the vector did not harbour a conventional multiple cloning site with an integrated promoter, allowing the expression of a cloned gene.

Due to the lack of an integrated promoter and missing information about the functionality of these genetic elements in *Amycolatopsis*, the access to genetic engineering was limited so far.

Therefore, the object of the present invention has been the construction and application of a plasmid-based gene expression system for *Amycolatopsis* sp. ATCC 39116 that allows efficient genetic engineering of this industrially relevant production strain.

DESCRIPTION OF THE INVENTION

A first object of the present invention is related to a new shuttle vector (p6apra) with resistance to apramycin obtainable in that shuttle vector pRLE6 of *E.coli*-*Amycolatopsis*

(a) is subjected to digestion with a suitable endonuclease (SmaI, XmaI) to remove the *npt* gene from said vector or the vector backbone is amplified by inverse PCR without the *npt* gene and

(b) the apramycin resistance gene *aac(3)VI* is inserted into the vector backbone by ligation,

and a corresponding process for obtaining shuttle vector p6apra, wherein said shuttle vector pRLE6 of *E.coli-Amylocatopsis*

- (a) is subjected to digestion with SmaI to remove the *npt* gene from said vector and
- (b) the apramycin resistance cassette of the transposon pMA5096 is inserted into the vector backbone by blunt end ligation.

In addition, further embodiments of the present invention concern expression vectors obtained by derivatisation of said shuttle vector and the corresponding processes. In detail:

(I) A first expression vector with additional restriction sites, obtainable in that

- (a) *lac*-promoter with the multiple cloning site of the plasmid pBluescript SK- is amplified via PCR
- (b) the PCR product is cloned into the EcoRV site of the p6apra vector according to Claim 1.

and a corresponding process for obtaining a first expression vector, wherein

- (a) *lac*-promoter with the multiple cloning site of the plasmid pBluescript SK- is amplified via PCR
- (b) the PCR product is cloned into the EcoRV site of the p6apra vector according to Claim 1.

(II) A second expression vector, obtainable in that

- (a) a 395-bp fragment of the genome of *Amycolatopsis* sp. ATCC 39116 upstream of the start codon of *vdh* (GTG) containing a promoter sequence is amplified via PCR,
- (b) a NcoI-site (CCATGG) is inserted into the reverse primer 6bp downstream of the Shine-Dalgarno sequence of *vdh* (AGGAG), and
- (c) the PCR product is cloned into the EcoRV site of the p6apra vector according to Claim 1.

and a corresponding process for obtaining a second promoted shuttle vector, wherein

- (a) a 395-bp fragment of the genome of *Amycolatopsis* sp. ATCC 39116 upstream of the start codon of *vdh* (GTG) containing a promoter sequence is amplified via PCR,
- (b) a NcoI-site (CCATGG) is inserted into the reverse primer 6bp downstream of the Shine-Dalgarno sequence of *vdh* (AGGAG), and
- (c) the PCR product is cloned into the EcoRV site of the p6apra vector according to Claim 1.

(III) A third promoted shuttle vector, obtainable in that

- (a) the promoter sequence of the kanamycin resistance gene (Km^r) is amplified via PCR, (b) a NcoI-site (CCATGG) is inserted into the reverse primer 9bp downstream of the Shine-Dalgarno sequence of *npt*, and
- (b) the PCR product is cloned into the EcoRV site of the p6apra vector according to Claim 1.

and a corresponding process for obtaining a third expression vector, wherein

(a) the promoter sequence of the kanamycin resistance gene (Km^r) is amplified via PCR, (b) a NcoI-site (CCATGG) is inserted into the reverse primer 9bp downstream of the Shine-Dalgarno sequence of *npt*, and

5 (b) the PCR product is cloned into the EcoRV site of the p6apra vector according to Claim 1.

(IV) A fourth expression vector, obtainable in that

(a) *ermE** promoter from *Saccharopolyspora erythraea* is removed from the plasmid pLAGO, and

10 (b) the fragment is cloned into the EcoRV site of the p6apra vector according to Claim 1.

and a process for obtaining a fourth expression vector, wherein

(a) *ermE** promoter from *Saccharopolyspora erythraea* is removed from the plasmid pLAGO, and

15 (b) the fragment is cloned into the EcoRV site of the p6apra vector according to Claim 1.

Surprisingly, it has been observed that the new expression vectors, obtained by inserting different promoter elements, overcome the drawbacks reported in the state of the art.

20 **More detailed description of the invention**

In a first step a pRLE6 derivative was constructed that conferred apramycin resistance instead of kanamycin. This was necessary, since it was observed that recombination events between the episomal and an inactive genomic copy of the kanamycin resistance gene *npt* occurs. Furthermore, a kanamycin resistant deletion mutant of *Amycolatopsis* sp. ATCC 25 39116 was used. The new transformation vector p6apra was also maintained without further modification under the selection of apramycin. Applicant was able to isolate plasmid-DNA from each tested clone. Therefore, the plasmid replicated autonomously from the genome and did not integrate. This was not the fact, if pRLE6 was used for the transformation of *Amycolatopsis* sp. ATCC 39116.

30 In order to generate a multiple cloning site like in conventional expression vectors, four different promoter sequences were inserted into the shuttle vector to enable the transcription of colinear cloned genes. After integration of each promoter, at least six unique restriction sites were obtained which could be used for cloning, respectively. In case of the two promoters, which were known to be functional in *Amycolatopsis* sp. ATCC 39116, the *vdh* and Km^r promoter, their genetic organization was successfully maintained by 35 introducing an additional NcoI-site. This restriction site allowed cloning the ATG start codon of a gene of interest six or nine base pairs downstream of the respective Shine-Dalgarno-sequence. As a third promoter the *lac*-promoter was chosen, which is useful to enable heterologous expression in a broad range of bacteria. Finally the *ermE**-promoter was 40 inserted, in order to achieve a strong constitutive expression in different actinomycetes [3].

In order to determine the functionality of the cloned promoters, the glucuronidase gene *gusA* was inserted into the respective p6apra derivatives. *gusA* was chosen as a reporter gene, since the activity of the encoded enzyme GUS can easily be detected directly on agar plates. Additionally, the activity can be assayed in a very simple and cheap but sensitive enzyme test [16]. Finally, *Amycolatopsis* sp. ATCC 39116 did not exhibit any inherent glucuronidase activity.

As a main requirement for the successful establishment of a plasmid-based expression system for *Amycolatopsis* sp. ATCC 39116 the stable replication of the new expression vectors was observed. All generated plasmids did not undergo any modification as it was previously observed, for *Amycolatopsis* sp. HR167 and other *Amycolatopsis* strains [14, 23].

Following the analysis of the genetic stability of the new vector system the functionality of the integrated promoters was analysed by using the reporter gene *gusA*. Since *Amycolatopsis* sp. ATCC 39116 does not exhibit an endogenous glucuronidase activity, the hydrolysis of the substrates X-Gluc and *p*-nitrophenyl- β -D-glucuronide can directly be correlated to the expression of GUS encoded by the reporter gene. Furthermore, GUS does not need any cofactors, and the activity is therefore only limited to the amount of enzyme [16].

Surprisingly, the transcription of *gusA* mediated by the *ermE**-promoter led to the highest glucuronidase activity. This was proven within both the qualitative assay on agar plates as well as the quantitative enzyme assay.

Gene expression activated by *PermE** led to a six-fold higher GUS-activity in comparison to the *Km^r* promoter, which is the second strongest. Furthermore, the glucuronidase activity in the soluble fraction of *Amycolatopsis* sp. ATCC 39116 p6permE::*gusA* was 75-fold higher than the activity of *Amycolatopsis* sp. ATCC 39116 p6pvdh::*gusA* and even 7550-fold higher than the activity *Amycolatopsis* sp. ATCC 39116 p6plac::*gusA*. The lower expression under the control of *lacP* is remarkable, due to the fact, that the promoter is commonly used in many different actinomycetes, including strains of *Nocardia*, *Gordonia* or *Rhodococcus*. Interestingly, the *lac*-promoter was also used in previous studies with *Amycolatopsis* sp. HR167 to enable the heterologous expression of foreign genes [18]. In this case the heterologous gene was cloned into pBluescript SK- under the control of *lacP*, and in a next step the whole plasmid was ligated with pRLE6.

The differences in the expression activation were also observable in SDS-PAGE analysis, which revealed a prominent protein signal with an apparent molecular weight of 69 ± 2 kDa for *Amycolatopsis* sp. ATCC 39116 p6permE::*gusA*. This band was missing in the sample of the control strain and was only very weak in the samples of the strains containing plasmids possessing the *lacP* or the *vdh* promoter. The apparent molecular weight was also in good agreement with the postulated size of the β -glucuronidase which is 68.2 kDa [12].

The new plasmids provide new capabilities for the expression of heterologous genes in *Amycolatopsis* sp. ATCC 39116. Especially the possibility to choose between different promoters, providing remarkable differences in the expression strength, makes genetic engineering of the industrially relevant actinomycete *Amycolatopsis* sp. ATCC 39116 more easy and efficient.

Bacterial strains, plasmids and cultivation conditions

All bacterial strains and plasmids used in this study are listed in Table 1. Cells of *Escherichia coli* were grown in Lysogeny Broth (LB) medium at 37 °C (Sambrook et al. 1989). Cells of *Amycolatopsis* sp. ATCC 39116 were grown at 45 °C in Caso medium (Merck, Darmstadt, Germany). For selection of plasmid harboring strains, antibiotics were added to the medium as follows: Kanamycin: 50 µg/ml for *E. coli*; Apramycin: 50 µg/ml for *E. coli* and *Amycolatopsis*. Cell growth was measured by determination of the optical density at 400 nm (*Amycolatopsis* sp. ATCC 39116) or 600 nm (*E. coli*).

DNA isolation and manipulation

Plasmid DNA was isolated from *E. coli* using the “peqGOLD Plasmid MiniPrep Kit I” (PEQLAB GmbH, Erlangen, Germany). Plasmid isolation from *Amycolatopsis* sp. ATCC 39116 was performed using the “Qiagen Plasmid Purification Kit (Mini)” (Qiagen GmbH, Hilden, Germany). Upon plasmid isolation from *Amycolatopsis* sp. ATCC 39116, the DNA was transferred to *E. coli* again, to yield a sufficient amount that could be further analyzed. DNA was digested by restriction endonucleases (Thermo Fisher Scientific GmbH, Schwerte, Germany) under the conditions described by the manufacturer. Phusion Hot-Start II high-fidelity DNA polymerase, T4 DNA ligase and T4 DNA polymerase (Thermo Fisher Scientific GmbH, Schwerte, Germany) were used according to the instructions of the manufacturer. Oligonucleotides were purchased from Eurofins MWG Synthesis GmbH (Ebersberg, Germany). DNA fragments were isolated from agarose gels or reaction mixtures using the “peqGOLD Gel Extraction Kit” (PEQLAB GmbH, Erlangen, Germany).

Transfer of DNA

Plasmids were transferred into *E. coli* by employing the CaCl₂-method (Sambrook et al. 1989), whereas the transfer of plasmids into *Amycolatopsis* sp. ATCC 39116 was performed by direct mycelia transformation as previously described.

Plasmid construction

The kanamycin resistance gene from pRLE6 [23] was replaced by the apramycin resistance gene from pMA5096 [1] to generate p6apra. For this purpose pRLE6 was digested with SmaI to release a 1006-bp fragment containing the whole coding sequence of *npt*. The apramycin resistance gene *aac(3)VI* was amplified by PCR using the Phusion Hot-Start II high-fidelity DNA polymerase and the oligonucleotides Apra_for and Apra_rev (Table 1). The amplified product was subsequently ligated with the SmaI-digested vector backbone of pRLE6. After transformation of *E. coli* Mach-1 T1, the resulting plasmid p6apra was isolated and sequenced. The vector provides a multiple cloning site consisting of seven unique restriction sites (EcoRV, NheI, BmtI, FspAI, DraI, HindIII, BamHI, see also Figure 1). After transformation of *E. coli* ER 2925 to yield Dam- and Dcm-unmethylated DNA, p6apra was transferred to *Amycolatopsis* sp. ATCC 39116 and resulting mutants were analyzed for a stable replication of the new plasmid.

To make the transformation vector suitable for heterologous expression in *Amycolatopsis* sp. ATCC 39116 four different promoters were integrated into the single EcoRV-site of p6apra as shown in **Figure 2**.

At first the whole multiple cloning site of pSK- including *lacZ* was amplified using the oligonucleotides pSK_MCS_for and pSK_MCS_rev (**Table 1**) and Phusion high-fidelity DNA polymerase. Furthermore, the promoter region of the kanamycin resistance gene of pRLE6 was amplified using the oligonucleotides pKm_for and pKm_NcoI_rev (**Table 1**). The reverse primer includes a NcoI-site (CCATGG) which allows to clone the start codon (ATG) of a gene of interest 9 bp downstream of the included Shine-Dalgarno-sequence of *npt*. Additionally the upstream region of *vdh* [10] was amplified using the oligonucleotides pvdh_for and pvdh_NcoI_rev (**Table 1**). The ATG within the NcoI-site of the reverse primer is located 6 bp downstream of the Shine-Dalgarno-sequence which was designed analogous to the genetic organization of the *vdh* open reading frame in the genome of *Amycolatopsis* sp. ATCC 39116.

The *ermE**-promoter was isolated from pIAGO [22] by digestion with KpnI/BamHI. The fragment was purified from an agarose gel and blunt ends were generated using T4 DNA polymerase.

Each of the four promoter fragments was cloned into the EcoRV site of p6apra via blunt end ligation. The resulting plasmids were transferred to *E. coli* Mach-1 T1, isolated, and subsequently sequenced to analyze the correct integration and orientation of the promoter fragments colinear to the residual multiple cloning site.

In order to investigate the functionality and expression strength of the cloned promoters, the glucuronidase gene *gusA* was isolated as SpeI/EcoRV fragment from pSETGUS (Myronovskyi et al. 2011) and was subsequently cloned into the NheI/DraI-linearized expression vectors (p6pKm, p6pvdh, p6permE) colinear to the integrated promoters. For p6plac, *gusA* was cloned into the SpeI/EcoRV sites provided by the additionally cloned MCS.

After transformation of *E. coli* ER 2925, the expression vectors were transferred to *Amycolatopsis* sp. ATCC 39116, and the resulting strains were analyzed for a stable replication of the new plasmids.

Preparation of crude cell extracts and soluble fractions

Cell pellets of *Amycolatopsis* sp. ATCC 39116 were resuspended in 3 to 4 ml of 50 mM potassium phosphate buffer (pH 7.0). Crude extracts were obtained by three passages through a French pressure cell (120 MPa). For the preparation of soluble fractions, cell debris was removed by centrifugation for 60 min at 20.000 x *g* at 4 °C. For subsequent enzyme assays, samples were stored on ice.

Glucuronidase enzyme assay

The spectrophotometric measurement of glucuronidase activity in cell lysates was accomplished as described before. The reaction was initiated by the addition of *p*-nitrophenyl-β-D-glucuronide. Formation of *p*-nitrophenol was observed at 415 nm ($\epsilon = 7.76 \text{ cm}^2/\mu\text{mol}$). Enzyme activity is stated in units (U). One unit is defined as the amount of enzyme which generates 1 μmol *p*-nitrophenol per min.

To detect β -glucuronidase activity on agar plates, the colonies were overlaid with 1ml of 1mM 5-bromo-4-chloro-3-indolyl-beta-D-glucuronic acid (X-Gluc) solution. After a short incubation colonies containing hydrolytic GUS activity turned blue because of the formation of 5,5'-dibromo-4,4'-dichloro indigo.

5

Polyacrylamide gel electrophoresis

Samples of the soluble fractions were analyzed for their protein contents according to the method of Bradford (1976). Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed in 12.5% (wt/vol) gels as described by [13]. Amounts of proteins were added as indicated in the text. Staining of proteins was performed with Serva Blue G [28]. The following molecular weight reference proteins were purchased from Thermo Fisher Scientific GmbH (Schwerte, Germany): "PageRuler Prestained Protein Ladder" and "Unstained Protein Molecular Weight Marker".

15 INDUSTRIAL APPLICATION

Another object of the present invention refers to plasmid expression system for *Amycolatopsis* sp. ATCC 39116 comprising at least one of the expression vectors according to any of the Claims 3, 5, 7 or 9.

Further on, the invention encompasses the use of at least one of the expression vectors (I) to (IV) for replication in *Amycolatopsis* sp. ATCC 39116 and for heterologous expression of genes in *Amycolatopsis* sp. ATCC 39116 respectively.

Also encompassed by the present invention is the use of *Amycolaptopsis* sp. ATCC 39116 containing at least one of the expression vectors (I) to (IV) in a process for the manufacture of vanillin.

Finally, the invention also covers a process for making nature-identic vanillin by fermentation of ferulic acid by means of microorganisms selected from *Amycolaptopsis* sp. ATCC 39116 containing at least one the expression vectors (I) to (IV)

RELEVANT LITERATURE

The following documents represent the relevant state of the art. The numbers in the specification refer to these documents.

[1] *Banh Q, Arenskötter M, Steinbüchel A*
Establishment of Tn5096-based transposon mutagenesis in *Gordonia polyisoprenivorans*.

35 **Appl Environ Microbiol 71:5077-5084 (2005)**

[2] *Becker J, Wittmann C*
Systems and synthetic metabolic engineering for amino acid production - the heartbeat of industrial strain development.
Curr Opin Biotechnol 23:718-726 (2012)

40

- [3] *Bibb MJ, Janssen GR, Ward JM*
Cloning and analysis of the promoter region of the erythromycin resistance gene (*ermE*) of *Streptomyces erythraeus*.
Gene 38:215-226 (1985)
- 5 [4] *Bibb MJ, White J, Ward JM, Janssen GR*
The mRNA for the 23S rRNA methylase encoded by the *ermE* gene of *Saccharopolyspora erythraea* is translated in the absence of a conventional ribosome-binding site.
Mol Microbiol 14:533-545 (1994)
- 10 [5] *Bradford MM*
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding.
Anal Biochem 72:248-254 (1976)
- 15 [6] *Converti A, Aliakbarian B, Domínguez JM, Vázquez GB, Perego P*
Microbial production of biovanillin. Brazilian
J Microbiol 41:519-530 (2010)
- 20 [7] *Davis JR, Goodwin LA, Woyke T, Teshima H, Bruce D, Detter C, Tapia R, Han S, Han J, Pitluck S Sello JK*
Genome sequence of *Amycolatopsis* sp. strain ATCC 39116, a plant biomass-degrading actinomycete.
J Bacteriol 194:2396-2397 (2012)
- 25 [8] *Di Gioia D, Luziatelli F, Negroni A, Ficca AG, Fava F, Ruzzi M*
Metabolic engineering of *Pseudomonas fluorescens* for the production of vanillin from ferulic acid.
J Biotechnol 156:309-316 (2011)
- 30 [9] European Commission (EC) Regulation No 1334/2008 of the European parliament and of the council of 16 December 2008 on flavourings and certain food ingredients with flavouring properties for use in and on foods and amending regulation (EC) no 1601/91 of the council, regulations (EC) no 2232/96 and (EC) no 110/2008 and directive 2000/13/EC.
- [10] *Fleige C, Hansen G, Kroll J, Steinbüchel A*
Investigation of the *Amycolatopsis* sp. strain ATCC 39116 vanillin dehydrogenase and its impact on the biotechnical production of vanillin.
Appl Environ Microbiol 79:81-90 (2013)
- 35 [11] *Fleige C, Hansen G, Kroll J, Steinbüchel A, Lambrecht S, Pesaro M, Hilmer J*
Microorganisms and methods for producing substituted phenols.
EP 0761817 A1

- [12] *Jefferson RA, Burgess SM, Hirsh D*
Beta-glucuronidase from *Escherichia coli* as a gene-fusion marker.
Proc Natl Acad Sci USA 83:8447-8451 (1986)
- 5 [13] *Laemmli UK*
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature 227:680-685 (1976)
- [14] *Lal R, Khanna R, Dhingra N, Khanna M, Lal S*
Development of an improved cloning vector and transformation system in
Amycolatopsis mediterranei (*Nocardia mediterranei*).
10 **J Antibiot 51:161-169 (1998)**
- [15] *Muheim A, Lerch K*
Towards a high-yield bioconversion of ferulic acid to vanillin.
Appl Microbiol Biotechnol 51:456-461 (1999)
- 15 [16] *Myronovskyi M, Welle E, Fedorenko V, Luzhetskyy A*
Beta-glucuronidase as a sensitive and versatile reporter in actinomycetes.
Appl Environ Microbiol 77:5370-5383 (2011)
- [17] *Olano C, Lombó F, Méndez C, Salas JA*
Improving production of bioactive secondary metabolites in actinomycetes by
metabolic engineering.
20 **Metab Eng 10:281-292 (2008)**
- [18] *Overhage J, Priefert H, Rabenhorst J, Steinbüchel A*
Biotransformation of eugenol to vanillin by a mutant of *Pseudomonas* sp. strain HR199
constructed by disruption of the vanillin dehydrogenase (*vdh*) gene.
Appl Microbiol Biotechnol 52:820-828 (1999)
- 25 [19] *Overhage J, Steinbüchel A, Priefert H*
Harnessing eugenol as a substrate for production of aromatic compounds with
recombinant strains of *Amycolatopsis* sp. HR167.
J Biotechnol 125:369-376 (2006)
- 30 [20] *Pickens LB, Tang Y, Chooi Y*
Metabolic engineering for the production of natural products.
Annu Rev Chem Biomol Eng 2:211-236 (2011)
- [21] *Plaggenborg R, Overhage J, Loos A, Archer JAC, Lessard P, Sinskey AJ, Steinbüchel A,*
Priefert H
Potential of *Rhodococcus* strains for biotechnological vanillin production from ferulic
acid and eugenol.
35 **Appl Microbiol Biotechnol 72:745-755 (2006)**

- [22] *Power P, Dunne T, Murphy B, Lochlainn LN, Rai D, Borissow C, Rawlings B, Caffrey P*
Engineered synthesis of 7-oxo- and 15-deoxy-15-oxo-amphotericins: Insights into
structure-activity relationships in polyene antibiotics.
Chem Biol 15:78-86 (2008)
- 5 [23] *Priefert H, Achterholt S, Steinbüchel A*
Transformation of the pseudonocardiaecae *Amycolatopsis* sp. strain HR167 is highly
dependent on the physiological state of the cells.
Appl Microbiol Biotechnol 58:454-460 (2002)
- 10 [24] *Priefert H, Rabenhorst J, Steinbüchel A*
Biotechnological production of vanillin.
Appl Microbiol Biotechnol 56:296-314 (2001)
- [25] *Rowe CJ, Cortes J, Gaisser S, Staunton J, Leadlay PF*
Construction of new vectors for high-level expression in actinomycetes.
Gene 216:215-223 (1998)
- 15 [26] *Sambrook J, Fritsch EF, Maniatis T*
Molecular cloning: A laboratory manual.
2nd edition. Cold Spring Harbor, New York.(1998)
- [27] *Tuteja D, Dua M, Khanna R, Dhingra N, Khanna M, Kaur H, Saxena DM, Lal R*
The importance of homologous recombination in the generation of large deletions in
20 hybrid plasmids in *Amycolatopsis mediterranei*.
Plasmid 43:1-11 (2000)
- [28] *Weber K, Osborn M*
The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide
gel electrophoresis.
25 **J Biol Chem 244:4406-4412 (1969)**
- [29] *Wilkinson CJ, Hughes-Thomas ZA, Martin CJ, Bohm I, Mironenko T, Deacon M,
Wheatcroft M, Wirtz G, Staunton J, Leadlay PF*
Increasing the efficiency of heterologous promoters in actinomycetes.
30 **J Mol Microbiol Biotechnol 4:417-426 (2002)**

EXAMPLES

Example 1

5 Construction of expression vectors

In order to construct a plasmid-based expression system for *Amycolatopsis* sp. ATCC 39116, the shuttle vector p6apra, conferring resistance to apramycin, was generated.

10 **Figure 1** provides a physical map of the new shuttle vector p6apra. ApraR: apramycin resistance cassette; pA-rep: origin of replication for *Amycolatopsis* from plasmid pA387; *oriV*: origin of replication for *E. coli* from plasmid pBR322. Unique restriction sites, which can be used for cloning, are presented

The former *E. coli*- *Amycolatopsis* shuttle vector pRLE6 was modified because we observed recombination events between the included kanamycin resistance gene and an inactive genomic copy of the *npt* gene. Furthermore, a different antibiotic resistance cassette was
15 necessary since we previously generated a kanamycin resistant deletion mutant of *Amycolatopsis* sp. ATCC 39116 that should serve as host as well. For this purpose we removed the *npt* gene of pRLE6 by digestion with *Sma*I and inserted the apramycin resistance cassette of the transposon pMA5096 by blunt end ligation into the vector backbone. After the exchange of the antibiotic resistance gene, the vector was transferred
20 to *Amycolatopsis* sp. ATCC 39116 and apramycin resistant mutants could be monitored. We were able to isolate plasmid DNA from each tested clone, which suggests that p6apra is maintained as an autonomous element. Furthermore, the vector replicates in a stable manner as no deletions or rearrangements were observed after isolation and analysis of the plasmid from the obtained mutants.

25 Based on the new shuttle vector, four derivatives with different promoters were generated. All promoter fragments were cloned into the single *EcoRV* site antilinear to the apramycin resistance cassette, respectively. As a result of this insertion at least five of the remaining unique restriction sites upstream of each promoter are available for cloning and expression of foreign DNA under control of these regulatory elements.

30 **Figure 2** provides physical maps of the generated expression vectors. ApraR: apramycin resistance cassette; pA-rep: origin of replication for *Amycolatopsis* from plasmid pA387; *oriV*: origin of replication for *E. coli* from plasmid pBR322. Integrated promoters and their directions are indicated by grey arrows. Unique restriction sites, which can be used for cloning, are presented.

35 To test different promoters in *Amycolatopsis* sp. ATCC 39116 we first chose the commonly used *lac*-promoter, which is reported to be functional in a broad range of bacteria and which is therefore used within various cloning vectors. To obtain additional restriction sites, we inserted the complete multiple cloning site of the commercially available plasmid pBluescript SK- into p6apra. For this the whole multiple cloning site including the *lac*-promoter was
40 amplified by PCR and subsequently cloned into the *EcoRV* site of p6apra.

As a second promoter, we inserted the upstream region of the previously characterized *vdh* gene of *Amycolatopsis* sp. ATCC 39116. For this purpose we amplified a 395-bp fragment

upstream of the start codon of *vdh* (GTG) that contains the promoter sequence as was shown in complementation experiments beforehand (data not shown). To maintain this functional genetic organization, we inserted a NcoI-site (CCATGG) in the reverse primer, which allows us to clone a gene of interest 6bp downstream of the putative Shine-Dalgarno sequence of *vdh* (AGGAG).

The same cloning strategy was used for the insertion of the promoter region of the kanamycin resistance gene (Km^r). Analogous to the *vdh*-promoter we maintained a distance of 9 bp to the native Shine-Dalgarno sequence of the *npt* gene by introduction of a NcoI site. The kanamycin resistance promoter was chosen since we knew from the use of pRLE6 and Km^r for the introduction of knock outs that *npt* is functionally transcribed in *Amycolatopsis* sp. ATCC 39116 under the control of this element.

Finally, we cloned the *ermE** promoter from *Saccharopolyspora erythraea*, which is a strong constitutive promoter and which is frequently used in actinomycetes if high-level expression is required (Wilkinson et al. 2002). The promoter was removed from the plasmid pIAGO by KpnI/BamHI digestion. Blunt ends were subsequently generated, and the fragment was again cloned into the EcoRV-site of p6apra.

All generated plasmids replicated in *Amycolatopsis* sp. ATCC 39116 without any observable rearrangements, and they can therefore be used for the heterologous expression of required genes.

Example 2

Expression of gusA in Amycolatopsis sp. ATCC 39116

In order to test the applicability of the heterologous promoters in *Amycolatopsis* sp. ATCC 39116, the β -glucuronidase GUS was chosen, encoded by the *gusA* gene as a reporter [16]. The activity of the β -glucuronidase can easily be detected on agar plates qualitatively and also quantitatively in a simple but sensitive spectrophotometric assay.

Initially *Amycolatopsis* sp. ATCC 39116 was tested for an inherent GUS activity to exclude a potential background signal in the control strains. The wild type strain did not exhibit any glucuronidase activity, which makes *gusA* a suitable reporter gene for our investigation.

To determine the functionality of the expression plasmids, the glucuronidase gene *gusA* was cloned as a reporter downstream and collinear to the promoters, respectively. As a control strain we additionally generated a promoterless version of p6apra containing only *gusA*.

After the transfer of the expression vectors, GUS activity was detected on agar plates for all strains except for the control strain that carried the promoterless *gusA* gene. For this purpose, the bacteria were incubated for 48 hours at 42°C on solid TSB agar and subsequently overlaid with the substrate X-Gluc as described in materials and methods. Differences in the expression strength of the cloned promoter fragments could be assumed even within this qualitative analysis. The expression strains carrying p6plac::*gusA* and p6pvdh::*gusA* exhibited only a faint blue color, while a strong coloring was observed with strains *Amycolatopsis* sp. ATCC 39116 p6pKm::*gusA* and *Amycolatopsis* sp. ATCC 39116 p6permE::*gusA*.

To further analyze the *gusA* expression under the control of the different promoters, the specific enzyme activity was determined in crude extracts of the four expression strains. The

different *Amycolatopsis* sp. ATCC 39116 expression strains were cultivated in TSB medium for 24 h at 42 °C. The cells were harvested after cultivation, soluble fractions were prepared, and the specific activity of the β -glucuronidase GUS was measured photometrically as described in materials and methods. The control strain carrying the promoterless plasmid p6apra::*gusA* was treated under the same conditions.

The activity assays revealed that no GUS activity was expressed by the control strain. In contrast to that all generated expression strains showed the formation of *p*-nitrophenol as observed spectrophotometrically by the increase of absorption at 415 nm. Quantitative analysis confirmed the assumption of an increasing expression strength with p6permE exhibiting the highest enzyme activity (**Table 2**). This was also obvious during the activity tests on agar plates. While *gusA* expression under the control of the *lac* and *vdh* promoter only led to an enzyme activity of 0.04 U/mg $\pm$ 0.00038 U/mg and 4.04 U/mg $\pm$ 0.071 U/mg, respectively, the strains carrying the Km^r-promoter and *PermE** exhibited very strong activities of 59.07 U/mg $\pm$ 1.50 U/mg and 302.20 U/mg $\pm$ 1.25 U/mg.

The expression of *gusA* was also obvious during SDS-PAGE analysis of the soluble fractions which revealed a prominent protein band at a size of approximately 69 $\pm$ 2 kDa. This signal was missing for the control strain, while the strongest protein band could be observed for the strain expressing *gusA* under the control of *PermE**.

Figure 3 shows the detection of GUS synthesis by different *gusA* expression strains via SDS-PAGE analysis. The samples were separated in a 12.5 % (wt/vol) SDS-polyacrylamide gel as described in materials and methods. The gel was stained with Serva Blue G. Lane

M1: Molecular weight marker: "PageRuler Prestained Protein Ladder", Lane

M2: Molecular weight marker: "Unstained Protein Molecular Weight Marker"; Lane

1: 30 μ g protein of the soluble fraction of the control strain *Amycolatopsis* sp. ATCC 39116 p6apra::*gusA*

2: 30 μ g protein of the soluble fraction of *Amycolatopsis* sp. ATCC 39116 p6plac::*gusA*

3: 30 μ g protein of the soluble fraction of *Amycolatopsis* sp. ATCC 39116 p6pvdh::*gusA*

4: 30 μ g protein of the soluble fraction of *Amycolatopsis* sp. ATCC 39116 p6pKm::*gusA*

5: 30 μ g protein of the soluble fraction of *Amycolatopsis* sp. ATCC 39116 p6permE::*gusA*.

Cells were grown in TSB medium for 24 h. Soluble fractions were obtained after cell disruption and subsequent centrifugation as described in materials and methods. The arrow indicates the corresponding signal of the putative *gusA* gene product.

In the following **Tables 1 and 2** provide Bacterial strains and plasmids as well as an overview of the specific GUS activity of the different expression strains.

Table 1

Bacterial strains and plasmids used in the study

Bacterial strains and plasmids	Description, sequence	Reference
Strains		
<i>Amycolatopsis</i> sp. ATCC 39116	wild type	American Type Culture Collection, No. 39116
<i>E. coli</i> Mach-1 T1	F ⁻ ϕ 80(<i>lacZ</i>) Δ M15 Δ <i>lacX74</i> <i>hsdR</i> (<i>r_K⁻ m_K⁺</i>) Δ <i>recA1398 endA1 tonA</i>	Invitrogen GmbH (Karlsruhe, Germany)
<i>E. coli</i> K12 ER 2925	<i>ara-14 leuB6 fhuA31 acly1 tsx78 glnV44 galK2 galT22 mcrA dcm-6 hisG4 rfbD1 R(zgb210::Tn10)TetS endA1 rpsL136 dam13::Tn9 xylA-5 mtl-1 thi-1 mcrB1 hsdR2</i>	New England Biolabs Inc. (Ipswich, MA, USA)
Plasmids		
pRLE6	5.8 kb, Km ^r	(Priefert et al. 2002)
pBluescript SK-(pSK-)	Ap ^r , <i>LacPOZ'</i> , T7 and T3-promoter	Agilent GmbH, Waldbronn, Germany
pIAGO	<i>ermE</i> *-promoter from <i>Saccharopolyspora erythraea</i> as 0.28-kb KpnI-BamHI fragment, Ts ^r , Ap ^r	(Power et al. 2008)
pMA5096	Ap ^r ; Apra ^r transposable plasmid comprising transposase Tn5096;	(Banh et al. 2005)
pSETGUS	<i>Streptomyces</i> integrative vector, <i>gusA</i> under control of <i>tipA</i> -promoter	(Myronovskiy et al. 2011)
p6apra	pRLE6 with Apra ^r from pMA5096 cloned into SmaI-sites	This invention

Table 1

Bacterial strains and plasmids used in the study (Cont.)

Bacterial strains and plasmids	Description, sequence	Reference
p6permE	p6apra with <i>ermE</i> *-promoter from pIAGO cloned into EcoRV-site	This invention
p6pKm	p6apra with Km ^r -promoter from pRLE6 cloned into EcoRV-site	This invention
p6pvdh	p6apra with promoter region of <i>vdh</i> -gene from <i>Amycolatopsis</i> sp. ATCC 39116 (Fleige et al. 2013) cloned into EcoRV-site	This invention
p6plac	p6apra with <i>multiple cloning site</i> of pSK-cloned into EcoRV-site	This invention
p6apra:: <i>gusA</i>	SpeI/EcoRV fragment of pSETGUS containing <i>gusA</i> cloned into NheI/DraI sites of p6apra	This invention
p6permE:: <i>gusA</i>	SpeI/EcoRV fragment of pSETGUS containing <i>gusA</i> cloned into NheI/DraI sites of p6permE	This invention
p6pKm:: <i>gusA</i>	SpeI/EcoRV fragment of pSETGUS containing <i>gusA</i> cloned into NheI/DraI sites of p6pKm	This invention
p6pvdh:: <i>gusA</i>	SpeI/EcoRV fragment of pSETGUS containing <i>gusA</i> cloned into NheI/DraI sites of p6pvdh	This invention
p6plac:: <i>gusA</i>	SpeI/EcoRV fragment of pSETGUS containing <i>gusA</i> cloned into SpeI/EcoRV-sites of p6plac	This invention

Table 1

Bacterial strains and plasmids used in the study (Cont.)

Bacterial strains and plasmids	Description, sequence	Reference
Oligonucleotides	Sequence 5' – 3'	
Apra_for	GTAGCGGGGATCCGGGGA	This invention
Apra_rev	GCTCGGTTTCATGTGCAGCTCC	This invention
pSK_MCS_for	GCCGATTTCGGCCTATTG	This invention
pSK_MCS_rev	GCGAGTCAGTGAGCGAGG	This invention
pKm_for	GCAAGCGAACCGBAATTG	This invention
pKm_NcoI_rev	CAACCATGGGAAACGATCCTCATCCTGTCT	This invention
pvdh_for	CCAGATGCGTGTACGGGTG	This invention
pvdh_NcoI_rev.	AGCCATGGGTCACTCCTGATGCG	This invention

5

Table 2

Specific GUS activity of the different expression strains

Expression strain	Specific GUS activity (U/mg)
<i>Amycolatopsis</i> sp. ATCC 39116 p6plac:: <i>gusA</i>	0.04 U/mg $\pm$ 0.0004 U/mg
<i>Amycolatopsis</i> sp. ATCC 39116 p6pvdh:: <i>gusA</i>	4.04 U/mg $\pm$ 0.071 U/mg
<i>Amycolatopsis</i> sp. ATCC 39116 p6pKm:: <i>gusA</i>	59.07 U/mg $\pm$ 1.50 U/mg
<i>Amycolatopsis</i> sp. ATCC 39116 p6permE:: <i>gusA</i>	302.20 U/mg $\pm$ 1.25 U/mg

CLAIMS

1. A new shuttle vector (p6apra) with resistance to apramycin obtainable in that shuttle vector pRLE6 of *E.coli-Amycolatopsis*
 - (a) is subjected to digestion with a suitable endonuclease (SmaI, XmaI) to remove the *npt* gene from said vector or the vector backbone is amplified by inverse PCR without the *npt* gene and
 - (b) the apramycin resistance gene *aac(3)VI* is inserted into the vector backbone by ligation.
2. A process for obtaining shuttle vector p6apra, wherein said shuttle vector pRLE6 of *E.coli-Amycolatopsis*
 - (a) is subjected to digestion with SmaI to remove the *npt* gene from said vector and
 - (b) the apramycin resistance cassette of the transposon pMA5096 is inserted into the vector backbone by blunt end ligation.
3. A first expression vector with additional restriction sites, obtainable in that
 - (a) *lac*-promoter with the multiple cloning site of the plasmid pBluescript SK is amplified via PCR
 - (b) the PCR product is cloned into the EcoRV site of the p6apra vector according to Claim 1.
4. A process for obtaining a first expression vector, wherein
 - (a) *lac*-promoter with the multiple cloning site of the plasmid pBluescript SK is amplified via PCR, and
 - (b) the PCR product is cloned into the EcoRV site of the p6apra vector according to Claim 1.
5. A second expression vector, obtainable in that
 - (a) a 395-bp fragment of the genome of *Amycolatopsis* sp. ATCC 39116 upstream of the start codon of *vdh* (GTG) containing a promoter sequence is amplified via PCR,
 - (b) a NcoI-site (CCATGG) is inserted into the reverse primer 6bp downstream of the Shine-Dalgarno sequence of *vdh* (AGGAG), and
 - (c) the PCR product is cloned into the EcoRV site of the p6apra vector according to Claim 1.
6. A process for obtaining a second promoted shuttle vector, wherein
 - (a) a 395-bp fragment gene of *Amycolatopsis* sp. ATCC 39116 upstream of the start codon of *vdh* (GTG) containing a promoter sequence is amplified via PCR,
 - (b) a NcoI-site (CCATGG) is inserted into the reverse primer 6bp downstream of the Shine-Dalgarno sequence of *vdh* (AGGAG), and

- (c) the PCR product is cloned into the EcoRV site of the p6apra vector according to Claim 1.
7. A third promoted shuttle vector, obtainable in that
- 5 (a) the promoter sequence of the kanamycin resistance gene (Km^r) is amplified via PCR, (b) a NcoI-site (CCATGG) is inserted into the reverse primer 9bp downstream of the Shine-Dalgarno sequence of *npt*, and
- (b) the PCR product is cloned into the EcoRV site of the p6apra vector according to Claim 1.
8. A process for obtaining a third expression vector, wherein
- 10 (a) the promoter sequence of the kanamycin resistance gene (Km^r) is amplified via PCR, (b) a NcoI-site (CCATGG) is inserted into the reverse primer 9bp downstream of the Shine-Dalgarno sequence of *npt*, and
- (b) the PCR product is cloned into the EcoRV site of the p6apra vector according to Claim 1.
- 15 9. A fourth expression vector, obtainable in that
- (a) *ermE** promoter from *Saccharopolyspora erythraea* is removed from the plasmid pLAGO, and
- (b) the fragment is cloned into the EcoRV site of the p6apra vector according to Claim 1.
- 20 10. A process for obtaining a fourth expression vector, wherein
- (a) *ermE** promoter from *Saccharopolyspora erythraea* is removed from the plasmid pLAGO, and
- (b) the fragment is cloned into the EcoRV site of the p6apra vector according to Claim 1.
- 25 11. A plasmid expression system for the order of Actinomycetales, containing several industrially relevant families, like Corynebacterineae, Pseudonocardineae or Streptomycineae comprising at least one of the expression vectors according to any of the Claims 1, 3, 5, 7 or 9.
12. The use of at least one of the expression vectors according to any of the Claims 1, 3, 5, 7 or 9 for replication in these bacteria.
- 30 13. The use of at least one of the expression vectors according to any of the Claims 1, 3, 5, 7 or 9 for heterologous expression of genes in these bacteria.
14. The use of recombinant bacteria containing at least one of the expression vectors according to any of the Claims 1, 3, 5, 7 or 9 in a process for the manufacture of Vanillin, Vanillic acid, Coniferylalkohol, or Coniferylaldehyd.
- 35 15. A process for making nature-identic vanillin by fermentation of ferulic acid or eugenol by means of microorganisms containing at least one of the expression vectors according to any of the Claims 1, 3, 5, 7 or 9.




Figure 1
Physical map of the new shuttle vector p6apra





Figure 2
Physical maps of the four generated expression vectors

**Figure 3**

Detection of GUS synthesis by different *gusA* expression strains via SDS-PAGE analysis

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP2014/076189

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
- a. (means)
- ☐ on paper
- ☒ in electronic form
- b. (time)
- ☒ in the international application as filed
- ☐ together with the international application in electronic form
- ☐ subsequently to this Authority for the purpose of search
2. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2014/076189

A. CLASSIFICATION OF SUBJECT MATTER
INV. C12N15/74 C12R1/01
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C12N C12R

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	H. PRIEFERT ET AL: "Transformation of the Pseudonocardia sp. strain HR167 is highly dependent on the physiological state of the cells", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 58, no. 4, 1 March 2002 (2002-03-01), pages 454-460, XP055106962, ISSN: 0175-7598, DOI: 10.1007/s00253-001-0920-5 page 456 - page 457 ----- -/--	1-15



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

6 March 2015

Date of mailing of the international search report

16/03/2015

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Herrmann, Klaus

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2014/076189

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	C. FLEIGE ET AL: "Investigation of the Amycolatopsis sp. Strain ATCC 39116 Vanillin Dehydrogenase and Its Impact on the Biotechnical Production of Vanillin", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 79, no. 1, 12 October 2012 (2012-10-12), pages 81-90, XP055106545, ISSN: 0099-2240, DOI: 10.1128/AEM.02358-12 abstract page 85, left-hand column -----	1-15
X	WO 2012/172108 A1 (SYMRISE AG [DE]; LAMBRECHT STEFAN [DE]; HILMER JENS-MICHAEL [DE]; PESA) 20 December 2012 (2012-12-20) the whole document -----	1-15
T	CHRISTIAN FLEIGE ET AL: "Construction of expression vectors for metabolic engineering of the vanillin-producing actinomycete Amycolatopsis sp. ATCC 39116", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 98, no. 14, 18 April 2014 (2014-04-18), pages 6387-6395, XP055148582, ISSN: 0175-7598, DOI: 10.1007/s00253-014-5724-5 the whole document -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2014/076189

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2012172108 A1	20-12-2012	EP 2721148 A1	23-04-2014
		US 2014087428 A1	27-03-2014
		WO 2012172108 A1	20-12-2012
